DABIGATRAN ETEXILAT LICONSA 75mg capsules medication leaflet

B01AE07 dabigatran etexilat • Blood and blood forming organs | Antithrombotic agents | Direct thrombin inhibitors

Dabigatran etexilate is an oral anticoagulant used for the prevention and treatment of blood clots. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Dabigatran etexilate works as a direct thrombin inhibitor, preventing the formation of blood clots. It is administered orally in capsule form, with the dosage adjusted based on the patient's condition and bleeding risk.

Side effects may include bleeding (nasal, gastrointestinal, or other types), dyspepsia (heartburn), nausea, or allergic reactions. It is contraindicated in patients with active bleeding, severe renal impairment, or hypersensitivity to the substance. It should also be used cautiously in patients with a high risk of bleeding.

General data about DABIGATRAN ETEXILAT LICONSA 75mg

Substance: dabigatran etexilat

Date of last drug list: 01-05-2025

Commercial code: W71009008

Concentration: 75mg

Pharmaceutical form: capsules

Quantity: 60

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: LABORATORIOS LICONSA, S.A. - SPANIA

Holder: LABORATORIOS LICONSA, S.A. - SPANIA

Number: 15923/2025/08

Shelf life: 2 years

Pharmaceutical forms available for dabigatran etexilat

Concentrations available for dabigatran etexilat

110mg, 150mg, 20mg, 30mg, 40mg, 50mg, 6.25mg/ml, 75mg

Other substances similar to dabigatran etexilat